Review
Published · Updated · 2 min read
In France, fewer than 4% of women aged 45 to 60 receive menopausal hormone therapy
What it means for practice
Assess menopausal symptom severity and treatment needs during consultations. In perimenopause, consider contraceptive needs alongside symptom control, bone health and vascular safety.
Summary
Under-prescription of therapy
According to the article, fewer than 4% of French women aged 45 to 60 receive menopausal hormone therapy (MHT), while a quarter of menopausal women report severe symptoms. These figures concern different described populations and do not establish the proportion of women with severe symptoms who receive treatment. Under-prescription of MHT was a central theme of the reported session and of a parliamentary report published in April 2025.
The transition to menopause
A separate session topic was effective contraception in perimenopause alongside symptom control, preservation of bone health and consideration of vascular safety. The introduction links this issue to the move away from high-dose progestogens, but the accessible excerpt does not provide the reasons or name specific medicines.
Session participants discussed available evidence, the parliamentary report’s 25 recommendations and barriers to prescribing MHT.
Limits of the available information
Only the beginning of the publication is accessible; registration is required to read further. The basis for the recommendations, specific treatment regimens and the balance of benefits and risks therefore cannot be assessed from this excerpt.
Source
-
Périménopause et ménopause : mieux accompagner la transition et sortir de la sous-prescription du THM. Gynécologie Obstétrique Pratique.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
